Top Gainers: Neurocrine Biosciences (NBIX), Axalta Coating (AXTA), ACCO Brands (ACCO), Criteo SA (CRTO)

Neurocrine Biosciences Inc. (NBIX) is up 7% in late trading following this morning’s announcement of AbbVie Inc. (ABBV) announcing positive top-line results from trial evaluating Elagolix in premenopausal women who suffer pain from endometriosis, a condition affecting an estimated 176 million women worldwide.

AbbVie, working with Neurocrine Biosciences in developing Elagolix, anticipates bringing a proposal to the FDA in 2017.

Shares of Axalta Coating Systems Ltd. (AXTA) are higher by nearly 11% to $24.09 in midday trading on Wednesday despite Philadelphia-based company reporting 4Q15 earnings of $0.24 per share on revenues of $1.01 billion, down 7.1% from a year ago. Analysts were expecting EPS of $0.25 on revenues of $1.01 billion.

ACCO Brands Corporation (ACCO) reported fourth quarter EPS of $0.29 before the opening bell Wednesday, compared to the consensus estimate of $0.28. Revenues decreased 10.4% from last year to $412.1 million. Analysts expected revenues of $399.2 million. For FY16, ACCO provided EPS guidance of $0.73-$0.77 versus consensus of $0.78 per share. The stock of the maker of office supplies is currently up 15% to $6.77 on 875K shares.

Shares of Criteo SA (CRTO) spiked up by more than 37 percent on Wednesday after the performance marketing specialist released strong fourth-quarter 2015 results. In its quarterly report, the Paris, France-based co. said it earned EUR 0.66 per share, 0.25 better than the consensus of EUR 0.41 per share analysts were expecting. Revenue rose 51.3% to EUR 145.75 million, above views for 138.24 million.

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.